Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 2
Ce profil est validé par 2 label.

Company

Mantis Therapeutics

Mantis Therapeutics_logo
24
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Leiden, Zuid-Holland, Netherlands

Send a message

Anglais

Mantis Therapeutics

Anglais

Mantis Therapeutics objective is to employ a recently developed immunotherapy in the form of a live attenuated Salmonella enterica serovar Typhimurium vector (BaCureTM) for cancer (CRC) immunotherapy. Our BaCureTM vector, specifically targets and colonizes multiple solid tumours and we aim to offer innovative targeted immunotherapy not only against CRC and also other cancer types. BaCureTM has shown the best-in-class efficacy against CRC...

See more

Mantis Therapeutics objective is to employ a recently developed immunotherapy in the form of a live attenuated Salmonella enterica serovar Typhimurium vector (BaCureTM) for cancer (CRC) immunotherapy. Our BaCureTM vector, specifically targets and colonizes multiple solid tumours and we aim to offer innovative targeted immunotherapy not only against CRC and also other cancer types. BaCureTM has shown the best-in-class efficacy against CRC and other cancer types. A single dose of BaCureTM elicits 100% CRC growth inhibition and 100% renal cell carcinoma (RCC) growth inhibition in pre-clinical models proving its superior efficacy to competitive bacterial vectors and other technologies. BaCureTM therefore offers a powerful alternative to current cancer (CRC) treatment options enabling us to tap into the large market of unmet medical needs. Importantly, in the future it can serve as a valid alternative for patients that show cancer recurrence and even be recommended as first line of treatment.

 

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

EUREKA Accelerated
Eureka is the world’s leading network for international R&D collaborations, represented in over 45 countries. It aims to boost the growth of SMEs, large companies, research organisations and universities through funding and supporting international R&D cooperation and providing investment-readiness services Through Eureka’s programmes, organisations can access funding and expert support. The Eureka label is given to companies who have been financed through Eureka programmes.
212 Entities
Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not receive funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1481 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
1920 Members
Access2EIC – Seal of Excellence
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
2130 Members
ESIL - Early Stage Investing Launchpad
A pan-european community to develop awareness-raising and capacity-building for business angels and other early-stage investors.
440 Members